PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of autoimmdisJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Autoimmune Dis. 2012; 2012: 404815.
Published online Feb 22, 2012. doi:  10.1155/2012/404815
PMCID: PMC3290816
Significant Changes in the Levels of Secreted Cytokines in Brains of Experimental Antiphospholipid Syndrome Mice
Assaf Menachem, 1 ,2 ,3 Joab Chapman, 1 ,2 ,3 * and Aviva Katzav 2 ,3
1Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
2Department of Neurology and Joseph Sagol Neuroscience Center, Sheba Medical Center, 52621 Ramat Gan, Israel
3Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel
*Joab Chapman: jchapman/at/post.tau.ac.il
Academic Editor: Jozélio Freire de Carvalho
Received October 3, 2011; Accepted November 28, 2011.
Abstract
Antiphospholipid syndrome (APS) is characterized by thromboses and neuropsychiatric manifestations possibly linked to brain inflammation. In order to examine the levels of proinflammatory and anti-inflammatory cytokines in experimental APS (eAPS) mice brains, we measured the levels of TNF-α, IFN-γ, and IL-10 in brain homogenates (cytosolic fractions) and in brain slices (secreted level) at 6, 15, and 24 weeks after immunization. We induced eAPS by immunization of Balb/c mice with β2-glycoprotein I (β2GPI), the major autoantigen in the disease and controls with adjuvant alone. We found increased levels of secreted TNF-α in eAPS mice for the entire experiment period. Cytosolic and secreted IL-10 and IFN-γ levels in eAPS mice were lower at 6 and 15 weeks and higher at 24 weeks after immunization. The results suggest that brain disease in APS is associated with significant and complex changes in proinflammatory and anti-inflammatory cytokines.
Articles from Autoimmune Diseases are provided here courtesy of
Hindawi Publishing Corporation